X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
https://www.globenewswire.com/news-release/2024/04/02/2856544/7767/en/MediciNova-Announces-Abstract-Regarding-Results-of-a-Clinical-Trial-of-MN-166-ibudilast-in-Glioblastoma-Accepted-for-Presentation-at-the-2024-American-Society-of-Clinical-Oncology-.html
https://www.globenewswire.com/news-release/2024/03/26/2852845/7767/en/MediciNova-Receives-a-Notice-of-Allowance-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Macular-Injury-in-Japan.html
https://www.globenewswire.com//news-release/2024/03/12/2844366/7767/en/MediciNova-Announces-New-Data-and-Results-of-MN-166-ibudilast-in-Chlorine-Gas-induced-Acute-Lung-Injury-Presented-at-the-63rd-Annual-Meeting-of-the-Society-of-Toxicology.html
https://www.globenewswire.com//news-release/2024/01/17/2810539/7767/en/MediciNova-Receives-a-Notice-of-Grant-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Macular-Injury-in-China.html
https://www.globenewswire.com//news-release/2023/12/21/2800380/7767/en/MediciNova-Announces-Abstract-Regarding-MN-166-ibudilast-in-Chlorine-Gas-induced-Lung-Injury-Accepted-for-Presentation-at-the-63rd-Annual-Meeting-of-the-Society-of-Toxicology.html
https://www.globenewswire.com/news-release/2023/12/06/2792155/7767/en/MediciNova-Receives-a-Notice-of-Decision-to-Grant-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Progressive-MS-in-Europe.html
https://www.globenewswire.com/news-release/2023/11/19/2782852/7767/en/MediciNova-Announces-New-Data-and-Results-of-a-Phase-2-Clinical-Trial-of-MN-166-ibudilast-in-Glioblastoma-Presented-at-the-28th-Annual-Meeting-of-the-Society-for-Neuro-Oncology.html
https://www.globenewswire.com//news-release/2023/10/10/2757986/7767/en/MediciNova-Receives-a-Notice-of-Allowance-for-a-New-Patent-Covering-the-Combination-of-MN-166-ibudilast-and-Riluzole-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS-in-Canad.html
https://www.globenewswire.com//news-release/2023/09/27/2750802/7767/en/MediciNova-Announces-Results-of-Studies-under-BARDA-Contract-to-Develop-MN-166-ibudilast-as-a-Medical-Countermeasure-Against-Chlorine-Gas-induced-Lung-Injury.html
https://www.globenewswire.com//news-release/2023/08/16/2726840/7767/en/MediciNova-Receives-a-Notice-of-Intention-to-Grant-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Macular-Injury-in-Europe.html
https://www.globenewswire.com/news-release/2023/06/29/2696800/7767/en/MediciNova-Announces-Presentation-of-Results-from-the-Phase-2b-Trial-of-MN-166-ibudilast-in-Alcohol-Use-Disorder-at-the-46th-Annual-Research-Society-on-Alcohol-RSA-Scientific-Meeti.html
https://www.globenewswire.com/news-release/2023/05/14/2668332/7767/en/MediciNova-Receives-a-Notice-of-Intention-to-Grant-for-a-New-Patent-Covering-MN-166-ibudilast-for-Patients-with-Microorganism-Infection-in-Europe.html
https://www.globenewswire.com/news-release/2023/03/09/2624673/7767/en/MediciNova-Announces-Additional-Extension-of-BARDA-Contract-to-Develop-MN-166-ibudilast-as-a-Medical-Countermeasure-Against-Chlorine-Gas-induced-Lung-Injury.html
https://www.globenewswire.com/news-release/2023/02/20/2611677/7767/en/MediciNova-Announces-New-Data-Regarding-MN-166-ibudilast-in-Glioblastoma-Tumor-Tissue-Analysis-Presented-at-the-20th-Annual-World-Congress-of-Society-for-Brain-Mapping-and-Therapeu.html
https://www.globenewswire.com/news-release/2023/01/12/2588326/7767/en/MediciNova-Announces-Completion-of-Enrollment-in-the-Phase-2-Clinical-Trial-Evaluating-MN-166-ibudilast-for-Treatment-of-Recurrent-and-Newly-Diagnosed-Glioblastoma.html
https://www.globenewswire.com//news-release/2023/01/05/2584169/7767/en/MediciNova-to-Meet-with-U-S-FDA-to-Discuss-Clinical-Development-of-a-Parenteral-Formulation-of-MN-166-ibudilast.html
https://www.globenewswire.com//news-release/2022/12/05/2567873/7767/en/MediciNova-Announces-Positive-Results-from-Secondary-Analysis-of-Phase-2-Trial-of-MN-166-ibudilast-Published-in-The-American-Journal-of-Drug-and-Alcohol-Abuse.html
https://www.globenewswire.com/news-release/2022/09/14/2516446/7767/en/MediciNova-Receives-Issue-Notification-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Glioblastoma.html
https://www.clinicaltrialsarena.com/news/medicinova-long-covid-trial/
https://www.globenewswire.com/news-release/2022/08/16/2498873/7767/en/MediciNova-Reaches-Agreement-to-Participate-in-Grant-Funded-Clinical-Trial-to-Evaluate-MN-166-ibudilast-for-the-Treatment-of-Long-COVID.html
https://www.globenewswire.com/news-release/2022/06/29/2471709/7767/en/MediciNova-Announces-Extension-of-BARDA-Contract-to-Develop-MN-166-ibudilast-as-a-Medical-Countermeasure-Against-Chlorine-Gas-induced-Lung-Injury.html
https://www.globenewswire.com/news-release/2022/06/08/2458506/7767/en/MediciNova-Announces-Positive-Top-Line-Results-from-Phase-2-Clinical-Trial-of-MN-166-ibudilast-in-Hospitalized-COVID-19-Patients-at-Risk-for-Acute-Respiratory-Distress-Syndrome.html
https://www.globenewswire.com/news-release/2022/04/13/2421520/7767/en/MediciNova-Announces-Completion-of-Enrollment-in-the-Phase-2-Clinical-Trial-of-MN-166-ibudilast-in-Hospitalized-COVID-19-Patients-at-Risk-for-Acute-Respiratory-Distress-Syndrome.html
https://www.globenewswire.com/news-release/2022/04/07/2418967/7767/en/MediciNova-Announces-Secondary-Analysis-of-Phase-2-Trial-of-MN-166-ibudilast-in-Alcohol-Use-Disorder-Published-in-Alcoholism-Clinical-and-Experimental-Research.html
https://www.globenewswire.com/news-release/2022/02/28/2392919/7767/en/MediciNova-Announces-MN-166-ibudilast-Identified-as-Potential-Beneficial-Pharmacotherapy-for-Treatment-of-Degenerative-Cervical-Myelopathy-in-Global-Spine-Journal.html
https://www.globenewswire.com/news-release/2022/02/22/2389064/7767/en/MediciNova-Announces-MN-166-ibudilast-Identified-as-Promising-Pharmacotherapy-for-Alcohol-Use-Disorder-in-Drugs.html
https://www.globenewswire.com/news-release/2022/01/27/2374144/7767/en/MediciNova-Receives-a-Notice-of-Intention-to-Grant-for-a-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Alcohol-Use-Disorder-in-Europe.html
https://www.globenewswire.com/news-release/2021/12/10/2349944/7767/en/MediciNova-Announces-MN-166-ibudilast-Poster-Presentation-at-the-32nd-International-Symposium-on-ALS-MND.html
https://www.globenewswire.com/news-release/2021/11/22/2338792/7767/en/MediciNova-Announces-New-Data-regarding-MN-166-ibudilast-in-Glioblastoma-Presented-at-the-26th-Annual-Meeting-of-the-Society-for-Neuro-Oncology.html
https://www.globenewswire.com/news-release/2021/11/10/2332159/7767/en/MediciNova-Announces-New-Data-regarding-MN-166-ibudilast-in-Uveal-Melanoma-Presented-at-the-CURE-OM-Global-Science-Meeting.html
https://www.globenewswire.com/news-release/2021/11/03/2327001/7767/en/MediciNova-Announces-New-Data-regarding-MN-166-ibudilast-in-Glioblastoma-to-be-Presented-at-the-Annual-Meeting-of-the-Society-for-Neuro-Oncology.html
https://www.globenewswire.com/news-release/2021/07/06/2258040/7767/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Ophthalmic-Disease.html
https://www.globenewswire.com/news-release/2021/06/28/2253702/7767/en/MediciNova-to-Conduct-Mouse-Study-under-Partnership-with-BARDA-to-Develop-MN-166-ibudilast-as-a-Medical-Countermeasure-Against-Chlorine-Gas-induced-Lung-Injury.html
https://www.globenewswire.com/news-release/2021/06/21/2250065/7767/en/MediciNova-Announces-Positive-Results-from-Phase-2-Trial-of-MN-166-ibudilast-in-Alcohol-Use-Disorder-Published-in-Nature-s-Translational-Psychiatry-Journal.html
https://www.globenewswire.com/news-release/2021/01/18/2160200/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-the-Combination-of-MN-166-ibudilast-and-Riluzole-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS-in-Japan.html
https://www.globenewswire.com/news-release/2020/12/29/2151193/0/en/MediciNova-Receives-Notice-of-Allowance-for-New-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Progressive-MS.html
https://www.globenewswire.com/news-release/2020/10/22/2112622/0/en/MediciNova-in-Collaboration-with-the-University-of-Sydney-and-the-Australasian-Gastro-Intestinal-Trials-Group-Announces-Plans-for-a-Multi-center-Phase-2b-Study-to-Evaluate-MN-166-i.html
https://seekingalpha.com/pr/17115082-medicinova-announces-collaboration-university-of-sydney-concord-cancer-centre-to-evaluate
https://www.globenewswire.com/news-release/2020/06/25/2053790/0/en/MediciNova-Announces-Positive-Preclinical-Results-Regarding-MN-166-ibudilast-in-Glioblastoma-GBM-Published-in-Frontiers-in-Immunology.html
https://www.clinicaltrialsarena.com/news/yale-ibudilast-covid-19-trial/
https://www.globenewswire.com/news-release/2020/04/20/2018952/0/en/MediciNova-Receives-Notice-of-Allowance-for-Second-Patent-Covering-MN-166-ibudilast-for-the-Treatment-of-Glioblastoma.html
https://www.clinicaltrialsarena.com/news/medicinova-ibudilast-covid-19-trial/
https://www.biospace.com/article/releases/medicinova-receives-notice-of-allowance-for-new-patent-covering-mn-166-ibudilast-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-in-canada/?s=95
http://www.globenewswire.com/news-release/2019/07/11/1881797/0/en/MediciNova-Announces-Phase-3-Clinical-Trial-Plan-for-MN-166-ibudilast-in-Progressive-MS.html
https://globenewswire.com/news-release/2019/01/08/1682502/0/en/MediciNova-Announces-Initiation-of-Enrollment-in-a-Clinical-Trial-of-MN-166-ibudilast-in-Glioblastoma.html
https://www.directorstalkinterviews.com/national-institute-on-alcohol-abuse-and-alcoholism-awards-r01-research-grant-to-ucla-for-phase-2b-clinical-trial-of-medicinovas-mn-166-ibudilast-in-alcohol-use-disorder/412756981
https://www.biospace.com/article/medicinova-s-drug-flunks-phase-ii-trial/
Market Place
Share 
